Company profile
Cibus, Inc.
NASDAQ: CBUS · Healthcare · Biotechnology
#733 of 1,422 Healthcare companies by revenue30th-percentile growth
EA Score
43DFH 31DQ 56GM 46SS 58
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, disclosure history · ↓ return on equity, growth stability
Methodology →Revenue TTM
$4.3M
Rev growth YoY (TTM)
-9.8%
Net income (FY)
-$127.1M
Employees
118
as of 2026-08-19
Market cap
$124.4M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.6M$3.6M2025
Net income-$127.1M-$127.1M2025
Operating income-$97.5M-$97.5M2025
Total assets$305.0M$305.0M2025
Liabilities$283.2M$283.2M2025
Equity$21.8M$21.8M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Cibus, Inc.’s revenue?
Cibus, Inc. booked $3.6M in FY2025 revenue, contracting 15% year over year — slower than 70% of Healthcare companies we track, at a -3492.3% net margin.
Peers · Healthcare
NovaBridge Biosciences36DTarget Group Inc.46DEVIO, Inc.——NeurAxis, Inc.45DRed Light Holland Corp.——Marker Therapeutics, Inc.36DNeighbors
San Diego →Key facts
CEOCraig Wichner
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: CBUS
Employees118
IPO date2017-07-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.